<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00793364</url>
  </required_header>
  <id_info>
    <org_study_id>MINERVA 01</org_study_id>
    <secondary_id>171108</secondary_id>
    <nct_id>NCT00793364</nct_id>
  </id_info>
  <brief_title>Effect of Plant Stanol Ester-Containing Spread on Estimated Cardiovascular Risk in Comparison to Mediterranean Diet</brief_title>
  <official_title>Effect of Plant Stanol Ester-Containing Spread Based on Extra Virgin Olive Oil on Estimated Cardiovascular Risk, and Lipid-Inflammatory-Haemostatic Factors in Comparison to Mediterranean Diet: A Randomized, Placebo-Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Atherosclerosis Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Minerva SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Atherosclerosis Society</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since it is very difficult to have the real thing (Mediterranean diet) we need to find an
      alternative to reduce cardiovascular disease (CVD) risk in subjects with moderate
      hypercholesterolaemia (a major CVD risk factor) living in western countries. Therefore, this
      proposed study is designed to assess if giving olive oil supplements, with or without stanol
      ester, is equivalent to following a Mediterranean diet. Furthermore, the stanol-olive oil
      combination may prove to be superior to olive oil alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Randomised, double blind, placebo controlled study Number of participants: 150 (3
      groups with 50 subjects each). Intervention: One group will be assigned to stanol ester
      spread (2 g/day) based on olive oil, another on spread with olive oil containing placebo
      stanol ester (in identical containers with the stanol ester spread). In the third group, a
      structured effort will be made to improve adherence to Mediterranean diet by at least 2
      points in a 10-level scale. Adherence to the Mediterranean diet will be improved by a
      dietician with detailed explanation of the composition of the diet, preparation of several
      week specific programs according to dietary preferences of the specific subject. Dietician
      interviews with a 5 day questionnaire on consumed foods will establish the degree of
      adherence to Mediterranean diet.

      Duration: 16 weeks (4 weeks of lifestyle advice and 12 weeks of treatment).

      Prespecified analyses:

        1. Postmenopausal women vs women with child bearing potential.

        2. Older (&gt;65 years of age) vs younger subjects,

        3. Subjects with impaired fasting glucose levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint: Change from baseline in cardiovascular (CVD) risk as assessed by the PROCAM and Framingham risk engines.</measure>
    <time_frame>three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in major CVD risk factors [TC, LDL-C, HDL-C, TG, apoB], in an inflammatory marker [C-reactive protein], in hemostatic parameters (PAI-I, fibrinogen), liver function tests at the end of the study vs baseline.</measure>
    <time_frame>three months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Stanol ester</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stanol-ester administration group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo spread</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo spread group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mediterranean diet group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mediterranean diet group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Stanol ester spread</intervention_name>
    <description>Stanol ester spread 20 g every day</description>
    <arm_group_label>Stanol ester</arm_group_label>
    <other_name>Dietary Supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo spread</intervention_name>
    <description>Placebo spread 20 g every day</description>
    <arm_group_label>Placebo spread</arm_group_label>
    <other_name>Dietary Supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mediterranean Diet</intervention_name>
    <description>Mediterranean Diet every day</description>
    <arm_group_label>Mediterranean diet group</arm_group_label>
    <other_name>Dietary Supplement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects over 45 years of age with mild hypercholesterolaemia (TC
             levels: 200 mg/dl - 230 mg/dl)

        Exclusion Criteria:

        Subjects with

          -  Established CVD (coronary heart disease, peripheral arterial disease, aortic aneurysm,
             or symptomatic carotid artery disease) or T2DM

          -  Chronic diseases (including liver diseases)

          -  Pregnancy

          -  Malignancies

          -  Unwillingness to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vasilios G Athyros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hippocration Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aristotelian University, Hippocration Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>55132</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <results_reference>
    <citation>Nguyen TT, Dale LC, von Bergmann K, Croghan IT. Cholesterol-lowering effect of stanol ester in a US population of mildly hypercholesterolemic men and women: a randomized controlled trial. Mayo Clin Proc. 1999 Dec;74(12):1198-206.</citation>
    <PMID>10593347</PMID>
  </results_reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2008</study_first_submitted>
  <study_first_submitted_qc>November 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2008</study_first_posted>
  <last_update_submitted>May 27, 2009</last_update_submitted>
  <last_update_submitted_qc>May 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vasilios G. Athyros, MD / Professor / Primary investigator</name_title>
    <organization>Hippocration Hospital</organization>
  </responsible_party>
  <keyword>Cholesterol, stanol-ester, mediterranean diet, cardiac risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

